Novo Nordisk Reports CagriSema Achieves Superior Weight Loss and HbA1c Reduction in Type 2 Diabetes Trial
I'm PortAI, I can summarize articles.
Novo Nordisk A/S has reported results from the REIMAGINE 2 phase 3 clinical trial for CagriSema, a combination treatment for type 2 diabetes. The trial involved 2,728 participants and showed that CagriSema led to a superior HbA1c reduction of up to 1.91 percentage points and weight loss of up to 14.2% compared to individual treatments. The safety profile was consistent with existing therapies. Detailed results will be presented at a conference in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments